• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Makary
Biotech

FDA stands behind decision to spurn mRNA flu filing

Following Moderna's public rebuke of the FDA's refusal to take up its application for a next-gen flu vaccine, the regulator has doubled down.
Eric Sagonowsky , Fraiser Kansteiner Feb 11, 2026 3:13pm
Warning symbol for radioactivity

Allogeneic CAR-T biotechs fight to escape 'nuclear winter'

Feb 11, 2026 11:00am
How AI Is reshaping clinical trials and market access
Sponsored

How AI Is reshaping clinical trials and market access

Feb 9, 2026 8:00am
liver

Madrigal pens $4.4B deal for siRNA drugs in fresh Rezdiffra play

Feb 11, 2026 7:40am
Article Primary Image 1jpg
Sponsored

The Data Multiplier Effect: The 4 Forces Changing Biometrics

Feb 9, 2026 8:00am
Moving van

Takeda consolidates Boston footprint

Feb 11, 2026 3:51pm
More News

Upstream posts Tezspire-like asthma efficacy in phase 2

Feb 11, 2026 7:24am

Moderna hit with FDA refusal-to-file letter for mRNA flu shot

Feb 10, 2026 7:45pm

Nektar eczema asset 'checked all of the boxes' in phase 2

Feb 10, 2026 10:55am

AstraZeneca's oral GLP-1 scored phase 2 wins, but no data yet

Feb 10, 2026 9:58am
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings